Insider Transactions in Q2 2025 at Processa Pharmaceuticals, Inc. (PCSA)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 01
2025
|
Patrick Lin Chief Business - Strategy Off |
SELL
Payment of exercise price or tax liability
|
Direct |
4,814
-11.06%
|
$0
$0.41 P/Share
|
|
Apr 01
2025
|
Patrick Lin Chief Business - Strategy Off |
BUY
Exercise of conversion of derivative security
|
Direct |
14,482
+24.96%
|
-
|
|
Apr 01
2025
|
Sian Bigora Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,311
-8.96%
|
$0
$0.41 P/Share
|
|
Apr 01
2025
|
Sian Bigora Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,059
+28.96%
|
-
|
|
Apr 01
2025
|
Wendy Guy Chief Administrative Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,482
+35.48%
|
-
|
|
Apr 01
2025
|
David Young Pres. Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
5,345
-2.4%
|
$0
$0.41 P/Share
|
|
Apr 01
2025
|
David Young Pres. Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
17,272
+7.2%
|
-
|